| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Lisdexamfetamine dimesylate |
| Brand | Tyvense® |
| Indication | For Attention Deficit Hyperactivity Disorder in children aged 6 years and over when response to previous methylphenidate treatment is considered clinically inadequate. |
| Assessment Process | |
| Rapid review commissioned | 09/02/2013 |
| Rapid review completed | 28/02/2013 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Not Recommended |